What’s Going On With Summit Therapeutics Stock On Monday?

All NewsOctober 20, 2025

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

What’s Going On With Summit Therapeutics Stock On Monday?

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

Wells Fargo sends surprising message to RV buyers about Camping World

Another holiday airline cancels all flights, eyes bankruptcy

Amazon’s $188 storage shed features a built-in pergola

AMD stock jumps 13% after 5-star analyst resets price target

Higher-than-expected October inflation sparks Treasury sell-off